8-hydroxy-2-(di-n-propylamino)tetralin, (r)-isomer profile

ID Source	ID
PubMed CID	6603866
CHEMBL ID	26998
CHEBI ID	103846
SCHEMBL ID	1682347
MeSH ID	M0329201

Synonym
BRD-K59765110-004-03-8
(r)-(+)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide
lopac-h-140
tocris-1080
tocris-0529
NCGC00015493-02
lopac-h-8250
NCGC00024635-01
NCGC00015493-01
NCGC00024986-01 ,
PDSP1_001710
LOPAC0_000638
PDSP2_001693
CHEBI:103846
NCGC00024986-03
CHEMBL26998 ,
7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol ((r)-oh-dpat)
(r)-7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol
7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol
r-(+)-7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol
7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol(8-oh-dpat)
(8-hydroxyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-dipropyl-amine
((r)-8-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-dipropyl-ammonium
bdbm50016777
(7r)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
CCG-204725
AKOS015966329
NCGC00015493-03
80300-09-0
SCHEMBL1682347
DTXSID00424964
(r)-8-hydroxy-2-dipropylaminotetralin
r(+)-8-oh-dpat
Q27181018
(r)-8-hydroxy-2-(di-n-propyl-amino)tetralin
SDCCGSBI-0050618.P002
NCGC00024986-08
TQP0826
(r)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol

Excerpt	Reference	Relevance
" The bioavailability of R-(+)-6 (7."	( Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity. Barf, T; Carlsson, A; Dijkstra, D; Duncan, JN; King, LJ; Martin, IJ; Nilsson, J; Smith, MW; Sonesson, C; Svensson, K, 1995)	0.29

Class	Description
tetralins	Compounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
dopamine D1 receptor	Homo sapiens (human)	Potency	7.3078	0.0052	1.3022	8.1995	AID624455
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	1.0000	0.1000	20.8793	79.4328	AID588453
USP1 protein, partial	Homo sapiens (human)	Potency	56.2341	0.0316	37.5844	354.8130	AID504865
GLS protein	Homo sapiens (human)	Potency	11.2202	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	27.3171	0.0008	11.3822	44.6684	AID686978
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	15.8489	0.0013	18.0743	39.8107	AID926; AID938
arylsulfatase A	Homo sapiens (human)	Potency	2.1331	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	15.8489	0.0355	20.9770	89.1251	AID504332
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	14.5891	0.0020	7.5337	39.8107	AID891
atrial natriuretic peptide receptor 1 precursor	Homo sapiens (human)	Potency	3.0131	0.1346	10.3950	30.1313	AID1347049
chromobox protein homolog 1	Homo sapiens (human)	Potency	0.0060	0.0060	26.1688	89.1251	AID488953
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	5.5303	0.0010	6.0009	35.4813	AID943; AID944
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	12.5893	0.0200	10.7869	31.6228	AID912
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	11.9047	1.0000	10.4756	28.1838	AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0042	0.0001	0.5326	10.0000	AID1656651; AID3830
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.3537	0.0000	0.6518	10.0000	AID55449; AID63410; AID64155; AID64156
Translocator protein	Rattus norvegicus (Norway rat)	Ki	0.0013	0.0001	0.6510	8.9300	AID3993
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0031	0.0001	0.7396	10.0000	AID1442392; AID3993; AID4103
5-hydroxytryptamine receptor 1D	Homo sapiens (human)	Ki	0.4010	0.0001	0.8087	10.0000	AID4906; AID4942
5-hydroxytryptamine receptor 7	Rattus norvegicus (Norway rat)	Ki	0.0273	0.0000	0.1480	3.1800	AID6652; AID6666
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	0.0480	0.0003	0.3806	10.0000	AID1656650
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.1790	0.0000	0.6020	10.0000	AID65787
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.8260	0.0000	0.4375	10.0000	AID65725
5-hydroxytryptamine receptor 1A	Mus musculus (house mouse)	Ki	0.0005	0.0005	0.4618	1.0000	AID4474
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of locomotion	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
smooth muscle contraction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
circadian rhythm	5-hydroxytryptamine receptor 7	Homo sapiens (human)
blood circulation	5-hydroxytryptamine receptor 7	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 7	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 7	Homo sapiens (human)
response to ethanol	D(3) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(3) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
learning or memory	D(3) dopamine receptor	Homo sapiens (human)
learning	D(3) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(3) dopamine receptor	Homo sapiens (human)
visual learning	D(3) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(3) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(3) dopamine receptor	Homo sapiens (human)
response to histamine	D(3) dopamine receptor	Homo sapiens (human)
social behavior	D(3) dopamine receptor	Homo sapiens (human)
response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(3) dopamine receptor	Homo sapiens (human)
response to morphine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	D(3) dopamine receptor	Homo sapiens (human)
acid secretion	D(3) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of oligodendrocyte differentiation	D(3) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(3) dopamine receptor	Homo sapiens (human)
musculoskeletal movement, spinal reflex action	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(3) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(3) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(3) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (138)

Assay ID	Title	Year	Journal	Article
AID197609	Half-minimal decrease in the accumulation of 5-HTP (5-Hydroxytryptophan) in non pretreated rat limbic brain at dose 0.25 umol/kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID180947	Forepaw treading (FPT) behavior was studied in rats after subcutaneous administration of 1 uM/Kg of compound; 7/7	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID174022	post-synaptic activity was determined by locomotor activity (LMA) in Non pretreated rats	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID170410	Effect of 5-HT accumulation in rat hippocampus at the dose of 0.32 umol/kg (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID6672	Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.
AID177255	Evaluated for receptor mediated feedback inhibition of 5-HTP formation in striatum tissue of rat brain when administered subcutaneously	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists.
AID174328	Inhibition of Dopamine receptor accumulation in limbic part of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID195533	Half-minimal decrease in the accumulation of DOPA (3,4-dihydroxyphenylalanine) in rat striatal brain; partial response at 50 uM/Kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID6452	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID3830	Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT	2000	Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7	Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
AID188183	The effect on the accumulation of 5-HTP in rat brain(striatum), by subcutaneous administration at a dose of 0.32(umol/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
AID174329	Inhibition of Dopamine receptor accumulation in striatum part of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID173462	DOPAC (3,4-dihydroxyphenylacetic acid) content of rat striatum reflecting DA metabolism and turnover	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID196909	Half-minimal decrease in the accumulation of DOPA (3,4-dihydroxyphenylalanine) in rat hemispheral brain; partial response at 50 uM/Kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID169705	No of rats exhibiting 5-HT motor syndrome tested in reserpinized rats at a subcutaneous dose of a. 0.1 umol/kg; 0 rats out of 4 showed activity	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID173460	5-HT content of rat hippocampus reflecting 5-HT metabolism and turnover	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID19541	Plasma half life was determined in rats	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID177254	Evaluated for receptor mediated feedback inhibition of 5-HTP formation in limbic tissue of rat brain when administered subcutaneously	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists.
AID177873	Inhibition of 5-Hydroxy tryptamine accumulation in striatum part of rat brain after subcutaneous administration	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID55449	Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride	2000	Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7	Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
AID1442392	Displacement of [3H]-8-OH-DPAT from 5-HT1A receptor in Sprague-Dawley rat cortex membranes after 15 mins by liquid scintillation spectrometric method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID195529	Half-minimal decrease in the accumulation of 5-HTP (5-Hydroxytryptophan) in rat striatal brain	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID57535	The effect on the accumulation of DOPA in rat brain(limbic), by subcutaneous administration at a dose of 0.32(umol/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
AID4179	Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID173463	HVA (Homovanillic acid)content of rat striatum reflecting DA metabolism and turnover	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID4169	Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID57537	The effect on the accumulation of DOPA in rat brain(striatum), by subcutaneous administration at a dose of 0.32(umol/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
AID6451	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID177298	Effect of compound on 5-Hydroxy transaminase accumulation upon subcutaneous administration in the limbic system of rat brain	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID4942	In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID4474	In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID197623	Half-minimal decrease in the accumulation of DOPA (3,4-dihydroxyphenylalanine) in rat limbic brain; partial response at 50 uM/Kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID6874	Approximate dose levels for a half maximal reduction of 5-HTP levels	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID49575	Maximum decrease in sympathetic nerve discharge(SND) observed at 1 mg/kg dose in cat	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID190309	Change in body temperature of rats upon administration after 30 minutes (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID6442	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID65787	In vitro binding affinity towards Dopamine receptor D3 by using [3H]spiperone as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID172342	Induction of clear-cut 5-HT motor syndrome in normal rats at the dose of 10 micro mol/kg	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID177326	In vivo evaluation for DOPA accumulation in the corpus striatum in male rats at highest test dose of 50 uM/Kg (sc); inactive	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID4103	In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID174323	Inhibition of 5-HTP accumulation in hemisphere of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID188770	behavioral syndrome(flat body posture and forepaw treading) at 0.25 mg/Kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID174324	Inhibition of 5-HTP accumulation in limbic part of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID172593	Change in body temperature was studied in rats upon subcutaneous administration of 1 uM/Kg of compound	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID124449	Maximum obtainable hypothermic effect up to 30 mg/kg dose in mice expressed as temperature decrease in degree Centigrade	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID4430	Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID6440	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID177486	Effect on Dopa accumulation upon subcutaneous administration in the limbic system of rat brain; I - inactive at highest dose (50 umol/kg)	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID196906	Half-minimal decrease in the accumulation of 5-HTP (5-Hydroxytryptophan) in rat hemispheral brain	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID1656650	Displacement of [3H]-5-carboxamidotryptamine from human 5-HT7A receptor expressed in HEK293 cell membranes incubated for 90 mins by scintillation counting method	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID6666	Binding affinity at rat 5-hydroxytryptamine 7 receptor.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.
AID1656652	Selectivity ratio of Ki for displacement of [3H]-5-carboxamidotryptamine from human 5-HT1A receptor expressed in HEK293T cell membranes to Ki for displacement of [3H]-5-carboxamidotryptamine from human 5-HT7 receptor expressed in HEK293 cell membranes	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID6652	Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT	2000	Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7	Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
AID178700	Subcutaneous dose giving half-maximal decrease of Dopa formation in the rat brain (limbic)	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID113319	Dose required to obtain hypothermic effect in mice following subcutaneous administration	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID177897	Inhibition of dopamine accumulation in limbic part of rat brain after subcutaneous administration; I= Inactive	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID177315	In vivo evaluation for 5-HTP accumulation in the corpus striatum in male rats (sc)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID230547	Ratio of serotonin turnover (5HIAA to 5-HT) in rat brain hippocampus compared to control	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID4175	Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID177484	Effect on Dopa accumulation upon subcutaneous administration in the hemispheres of rat brain; I - inactive at highest dose (50 umol/kg)	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID64155	In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID178697	Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain hemispheres (cortex)	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID173461	DA (dopamine) content of rat striatum reflecting DA metabolism and turnover	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID6453	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID174327	Inhibition of Dopamine receptor accumulation in hemisphere of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID230548	Ratio of turnover (DOPAC to DA) in rat brain striatum compared to control.	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID188765	uM/kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID4906	In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID172481	Induction of clear-cut 5-HT motor syndrome in reserpine (5 mg/kg, sc) pretreated rats at the dose of 1.0 micro mol/kg	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID177333	In vivo evaluation for DOPA accumulation in the hemispheres in male rats at highest test dose of 50 uM/Kg (sc); inactive	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID170411	Effect of 5-HT accumulation in rat hippocampus at the dose of 1.0 umol/kg (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID4023	Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID170421	Effect of accumulation of DOPA in rat striatum at the dose of 1.0 umol/kg	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID63410	Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID170414	Effect of DOPA accumulation in rat striatum at the dose of 0.32 umol/kg (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID177319	In vivo evaluation for 5-HTP accumulation in the hemispheres in male rats (sc)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID178702	Subcutaneous dose giving half-maximal decrease of Dopa formation in the rat brain (striatum)	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID177294	Effect of compound on 5-Hydroxy transaminase accumulation upon subcutaneous administration in the corpus striatum of rat brain	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID4071	Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID1656651	Displacement of [3H]-5-carboxamidotryptamine from human 5-HT1A receptor expressed in HEK293T cell membranes incubated for 90 mins by scintillation counting method	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID188763	Number of rats displaying the 5-HT syndrome or leaving the cage out of the number of rats tested	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID177253	Evaluated for receptor mediated feedback inhibition of 5-HTP formation in hemisphere of rat brain when administered subcutaneously	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists.
AID188181	The effect on the accumulation of 5-HTP in rat brain(limbic), by subcutaneous administration at a dose of 0.32(umol/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
AID4171	Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID6445	Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID177871	Inhibition of 5-Hydroxy tryptamine accumulation in limbic part of rat brain after subcutaneous administration	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID3168	Dose to reduce neuronal firing against 5-HT cells in rats (iv)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID178695	Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain (striatum)	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID177869	Inhibition of 5-Hydroxy tryptamine accumulation in hemispheres of rat brain after subcutaneous administration	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID3457	Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID189795	5-HT (serotonin) turnover in rat hippocampus (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID195387	Half-minimal decrease in the accumulation of 5-HTP (5-Hydroxytryptophan) in non pretreated rat striatal brain at dose 0.25 umol/kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID17943	Oral bioavailability in rat	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID177899	Inhibition of dopamine accumulation in striatum part of rat brain after subcutaneous administration; I= Inactive	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID65725	Displacement of [3H]spiperone from dopamine receptor D2	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID169561	No of rats exhibiting 5-HT motor syndrome tested in reserpinized rats at a subcutaneous dose of 0.32 umol/kg; 4 rats out of 4 showed activity	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
AID173459	5-HIAA (5-Hydroxyindoleacetic acid) content of rat hippocampus reflecting 5-HT metabolism and turnover	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID180770	Flat body posture behavior was studied in rats after subcutaneous administration of 1 uM/Kg of compound; 7/7	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID55589	Dose to reduce neuronal firing against DA cells (antagonist) in rats (iv)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID3993	Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID177296	Effect of compound on 5-Hydroxy transaminase accumulation upon subcutaneous administration in the hemisphere of rat brain	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID174325	Inhibition of 5-HTP accumulation in striatum part of rat brain after subcutaneous administration of compound before 60 min to death	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID197613	Half-minimal decrease in the accumulation of DOPA (3,4-dihydroxyphenylalanine) in non pretreated rat limbic brain at dose 0.25 umol/kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID4173	Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID170419	Effect of accumulation of DOPA in rat striatum at the dose of 0.32 umol/kg	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID189797	Dopamine (DA) turnover in rat corpus striatum	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID64156	In vitro binding affinity towards Dopamine receptor D2 by using [3H]spiperone as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID177321	In vivo evaluation for 5-HTP accumulation in the limbic system in male rats (sc)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID188911	behavioral syndrome(flat body posture and forepaw treading) at 0.25 ug/Kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID172487	Compound was tested for 5-HT behavioral response in reserpine pretreated rats; +5HT syndrome	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID177337	In vivo evaluation for DOPA accumulation in the limbic system in male rats at highest test dose of 50 uM/Kg (sc); inactive	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID177481	Effect on Dopa accumulation upon subcutaneous administration in the carpus striatum of rat brain; I - inactive at highest dose (50 umol/kg)	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
AID197625	In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID47963	Dose required to reduce sympathetic nerve discharge in mice following intravenous administration	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID178693	Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain (limbic)	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID170415	Effect of DOPA accumulation in rat striatum at the dose of 1.0 umol/kg (p<0.01)	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
AID171514	Cage leaving response was studied in rats after subcutaneous administration of 1 uM/Kg of compound; 0/7	1995	Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1	Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
AID195520	Half-minimal decrease in the accumulation of DOPA (3,4-dihydroxyphenylalanine) in non pretreated rat striatal brain at dose 0.25 umol/kg	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (18.52)	18.7374
1990's	7 (25.93)	18.2507
2000's	3 (11.11)	29.6817
2010's	6 (22.22)	24.3611
2020's	6 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phenethylamine phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016. 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.	2.15	1	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
tryptamine [no description available]	2.15	1	aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines	human metabolite; mouse metabolite; plant metabolite
7-hydroxy-2-n,n-dipropylaminotetralin 7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation	1.96	1	tetralins
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	3.23	6	phenols; tertiary amino compound; tetralins	serotonergic antagonist
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.15	1	amphetamines; dimethoxybenzene; organoiodine compound
sk&f 10047 SKF-10,047 : An organic heterotricyclic compound that is metazocine in which the methyl group at the N-position is replaced by an allyl group.	2.15	1
1-(1-naphthyl)piperazine 1-(1-naphthyl)piperazine: serotonin agonist; structure given in first source	2.01	1	N-arylpiperazine
1-(2-methoxyphenyl)piperazine 1-(2-methoxyphenyl)piperazine: RN given refers to parent cpd	2.01	1	piperazines
monomethylpropion monomethylpropion: metabolite of dimethylpropion; structure given in first source. 2-methylamino-1-phenylpropan-1-one : An aromatic ketone that is propiophenone in which the hydrogen alpha- to the keto group has been replaced by a methylamino group.. methcathinone : A racemate comprising equal amounts of (R)- and (S)-methcathinone.	2.15	1	aromatic ketone; secondary amino compound
3,4-methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.	2.15	1	benzodioxoles
n-methyl-3,4-methylenedioxyamphetamine N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.. 3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.	2.15	1	amphetamines; benzodioxoles	neurotoxin
5-carboxamidotryptamine 5-carboxamidotryptamine: agonist of 5-HT receptor; structure given in first source	2.41	2	tryptamines
methylbufotenin 5-methoxy-N,N-dimethyltryptamine : A tryptamine alkaloid that is N,N-dimethyltryptamine substituted by a methoxy group at position 5.	2.01	1	aromatic ether; tertiary amino compound; tryptamine alkaloid	hallucinogen; plant metabolite
5-methoxytryptamine 5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.	2.01	1	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	2.95	4	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.15	1	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.15	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
fenfluramine Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.	2.15	1	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
p-hydroxyamphetamine p-Hydroxyamphetamine: Amphetamine metabolite with sympathomimetic effects. It is sometimes called alpha-methyltyramine, which may also refer to the meta isomer, gepefrine.	2.15	1	amphetamines
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.15	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
octopamine Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.	2.15	1	phenylethanolamines; tyramines	neurotransmitter
tyramine [no description available]	2.15	1	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
lysergic acid diethylamide Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.	2.39	2	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	2.15	1	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
etryptamine etryptamine: RN given refers to cpd without isomeric designation	2.15	1	indoles
indopan indopan: RN given refers to parent cpd without isomeric designation. alpha-methyltryptamine : A tryptamine derivative having a methyl substituent at the alpha-position.	2.15	1	tryptamines
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	2.15	1	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
bufotenin Bufotenin: A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.. bufotenin : A tertiary amine that consists of N,N-dimethyltryptamine bearing an additional hydroxy substituent at position 5.	2.01	1	tertiary amine; tryptamine alkaloid	coral metabolite; hallucinogen
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.15	1	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
2,4,5-trimethoxyphenylisopropylamine 2,4,5-trimethoxyphenylisopropylamine: RN given refers to parent cpd; structure	2.15	1
2,5-dimethoxy-4-bromoamphetamine 2,5-dimethoxy-4-bromoamphetamine: RN given refers to (alpha)-isomer; a serotonin agonist that interferes with Meth A tumor growth in mice by selective vasoconstrictive action	2.15	1
cathinone cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.	2.15	1	2-aminopropiophenone; monoamine alkaloid	central nervous system stimulant; psychotropic drug
2,5-dimethoxyamphetamine 2,5-dimethoxyamphetamine: RN given refers to parent cpd without isomeric designation	2.15	1
2-(2,5-dimethoxyphenyl)ethanamine [no description available]	2.15	1	dimethoxybenzene
2,5-dimethoxy-4-methylamphetamine 2,5-Dimethoxy-4-Methylamphetamine: A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.	2.15	1
n,n-dipropyl-2-aminotetralin N,N-dipropyl-2-aminotetralin: RN given refers to parent cpd	1.98	1
4-methoxymethamphetamine 4-methoxymethamphetamine: does not behave as a simple amphetamine-like agent; RN given refers to parent cpd without isomeric designation; structure given in first source	2.15	1
uh 301 UH 301: structure given in first source	2.9	4
3-methoxyamphetamine 3-methoxyamphetamine: RN given refers to cpd without isomeric designation	2.15	1
n-desmethylmethoxyphenamine N-desmethylmethoxyphenamine: metabolite of methoxyphenamine; RN given refers to parent cpd without isomeric designation	2.15	1
5-hydroxy-2-n,n-dipropylaminotetralin 5-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation	1.96	1
8-(di-n-propylamino)-6,7,8,9-tetrahydro-3h-benz(e)indole-1-carbaldehyde 8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz(e)indole-1-carbaldehyde: RN refers to (+-)-isomer; structure given in first source	1.98	1
8-methoxy-2-(di-n-propylamino)tetralin 8-methoxy-2-(di-n-propylamino)tetralin: RN given refers to parent cpd without isomeric designation	2.15	1
norpseudoephedrine norpseudoephedrine: major metabolite of diethylpropion in man under acidic urine conditions; RN given refers to cpd without isomeric designation;. cathine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1S,2S-stereoisomer).	2.15	1	amphetamines; phenethylamine alkaloid	central nervous system stimulant; plant metabolite; psychotropic drug
dironyl dironyl: pronounced antifertility agent in rats; lactation suppressor in other species; serotonin antagonist; RN given refers to parent cpd; structure	1.97	1	organic molecular entity
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.15	1	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
sk&f 10047 [no description available]	2.15	1
7-hydroxy-2-n,n-dipropylaminotetralin, (r)-isomer [no description available]	2.37	2
ms-245 N,N-dimethyl-2-(1-(benzenesulfonyl)-5-methoxy-1H-indol-3-yl)ethylamine: a 5-HT(6) receptor ligand; structure in first source	2.15	1
4-iodo-2,5-dimethoxyphenylisopropylamine, (r)-isomer [no description available]	2.15	1
u 92016a [no description available]	1.98	1
2,5-dimethoxy-4-bromoamphetamine, (r)-isomer [no description available]	2.15	1
mephedrone mephedrone: a beta-keto (bk) designer drug; Central Nervous System Stimulants. mephedrone : An aromatic ketone that is propiophenone substituted at C-4 and at C-beta with methyl and methylamino groups respectively. It is a synthetic stimulant and entactogen drug of the amphetamine and cathinone classes.	2.15	1	amphetamines; aromatic ketone; secondary amino compound	environmental contaminant; xenobiotic

Condition	Relationship Strength	Studies
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Contact Dermatitis [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Itching [description not available]	2.21	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

8-hydroxy-2-(di-n-propylamino)tetralin, (r)-isomer

Cross-References

Synonyms (39)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (24)

Potency Measurements

Inhibition Measurements

Biological Processes (131)

Molecular Functions (13)

Ceullar Components (23)

Bioassays (138)

Research

Studies (27)

Market Indicators

Research Demand Index: 11.61

Study Types

8-hydroxy-2-(di-n-propylamino)tetralin, (r)-isomer

Cross-References

Synonyms (39)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (24)

Potency Measurements

Inhibition Measurements

Biological Processes (131)

Molecular Functions (13)

Ceullar Components (23)

Bioassays (138)

Research

Studies (27)

Market Indicators

Research Demand Index: 11.61

Study Types

Related Drugs (54)

Related Conditions (9)